Metastatic melanomas are subdivided by their mutation profile into four subtypes BRAF driven (about 52%), NRAS driven (28%), Neurofibromin 1 (NF1) mutated (14%) and in “triple wild type” [74]. Here, BRAF is linked to melanoma.